Research Topics
| Matthew KulkeSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:3555-61. 2006..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
Systemic therapy for advanced pancreatic neuroendocrine tumorsMatthew H Kulke
Program in Neuroendocrine and Carcinoid Tumors, Dana Farber Brigham and Women s Cancer Center, Boston, MA Electronic address
Semin Oncol 40:75-83. 2013..Recently, the biologically targeted agents everolimus and sunitinib were approved for use in patients with metastatic disease. Novel agents, as well as novel drug combinations, are currently under investigation...- Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancerMatthew H Kulke
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Thorac Cardiovasc Surg 127:1579-86. 2004.... 
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke
Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 27:5506-12. 2009..We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study...- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 15:338-45. 2009..We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens... - Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:401-6. 2006..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors... - Activity of sunitinib in patients with advanced neuroendocrine tumorsMatthew H Kulke
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 26:3403-10. 2008..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients... - Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 25:4787-92. 2007..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine... - Gastrointestinal neuroendocrine tumors: a role for targeted therapies?Matthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
Endocr Relat Cancer 14:207-19. 2007..Ongoing randomized studies should help better define the role these and other targeted agents will play in the future treatment of patients with this disease... - A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
Dig Dis Sci 51:1033-8. 2006..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors... - A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinomaMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Invest 24:346-50. 2006..9 months and the median overall survival time was 7.8 months. We conclude that vinorelbine has minimal toxicity but only minor antitumor activity in patients with advanced gastroesophageal adenocarcinoma... - Advances in the treatment of neuroendocrine tumorsMatthew Kulke
Dana Farber Cancer Institute, Boston, MA 02115, USA
Curr Treat Options Oncol 6:397-409. 2005..Larger, randomized trials, along with the evaluation of surrogate endpoints of biologic activity, may be necessary to establish the potential clinical benefit of these novel agents... - NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
Pancreas 39:735-52. 2010..We provide an overview of well-differentiated NETs of the stomach and pancreas and describe consensus guidelines for the treatment of patients with these malignancies... - A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumorsMatthew H Kulke
Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Chemother Pharmacol 68:293-300. 2011..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors... - Metastatic pancreatic cancerMatthew H Kulke
Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Treat Options Oncol 3:449-57. 2002..Palliative procedures, such as biliary or duodenal stenting and celiac plexus blockade, should be considered in conjunction with systemic therapy in patients with specific complications from pancreatic cancer... - Recent developments in the pharmacological treatment of advanced pancreatic cancerMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Investig Drugs 12:983-92. 2003..A number of novel chemotherapeutic and biological agents also appear promising and are likely to play a future role in the treatment of patients with advanced pancreatic cancer... - Neuroendocrine tumours: clinical presentation and management of localized diseaseMatthew H Kulke
Dana Farber Cancer Institute and Harvard Medical School, Department of Medical Oncology, Boston, MA 0215, USA
Cancer Treat Rev 29:363-70. 2003..In recent years, improved diagnostic techniques, increased recognition of neuroendocrine tumour subtypes, and new therapeutic modalities have enhanced clinicians' ability to detect and appropriately treat these malignancies... - Advanced pancreatic cancer: is there a role for combination therapy?Matthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Expert Rev Anticancer Ther 3:729-39. 2003..Increasingly, attention has turned to a number of novel chemotherapeutic and biologic agents that appear promising and are likely to play an important future role in the treatment of patients with this disease... - A Phase II trial of gemcitabine for metastatic neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer 101:934-9. 2004..Gemcitabine is generally well tolerated and possesses demonstrated activity against a wide range of malignancies. The authors assessed the efficacy of gemcitabine in the treatment of patients with metastatic neuroendocrine tumors... - A phase II study of docetaxel in patients with metastatic carcinoid tumorsMatthew H Kulke
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Invest 22:353-9. 2004..Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel. Although the treatment was well tolerated, no objective radiologic responses were observed. Novel, more effective agents are needed for this disease... - Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumorsMatthew H Kulke
Dana Farber Cancer Institute, Boston MA, USA
J Hematol Oncol 4:29. 2011.... - New developments in the treatment of gastrointestinal neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Oncol Rep 9:177-83. 2007..Continued investigation of these agents should render a better understanding of their efficacy in patients with advanced neuroendocrine tumors... - Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:1892-7. 2006..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer... - A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan
Dana Farber Partners Cancer Care Gastrointestinal Cancer Center, Brigham and Women s Hospital, Dana Farber Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA
Cancer Invest 21:505-11. 2003.... - A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagusMatthew H Kulke
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Cancer Invest 24:229-34. 2006..Our findings therefore support the continued use of epirubicin rather than doxorubicin in combination chemotherapy regimens for advanced gastroesophageal cancer... - DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumorLynn-Kristin Bracht
Center for Neuro-Oncology, Boston, MA, USA
J Clin Oncol 26:4843-4. 2008 - A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancerMatthew H Kulke
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer J 8:395-9. 2002..The median progression-free survival time was only 1.6 months, and the median survival time was 3.9 months. DISCUSSION: Troglitazone is not an active agent for the treatment of metastatic colorectal cancer... - Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, MA 02115, USA
Dig Dis Sci 53:564-70. 2008.... - Progress in the treatment of neuroendocrine tumorsJennifer A Chan
Gastrointestinal Cancer Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Curr Oncol Rep 11:193-9. 2009..Additionally, agents targeting the vascular endothelial growth factor pathway and mammalian target of rapamycin have shown preliminary evidence of activity and are currently being evaluated in large randomized studies... - A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaDavid P Ryan
Gastrointestinal Cancer Center, Dana Farber Partners Cancer Care, Boston, Massachusetts, USA
Cancer 94:97-103. 2002..Chemotherapy with gemcitabine is the standard first-line treatment. In a Phase II trial at one academic cancer center, the clinical safety and activity of combining gemcitabine and docetaxel were assessed... - A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinomaAndrew X Zhu
Massachusetts General Hospital Cancer Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
Oncologist 10:392-8. 2005..Therefore, we performed a phase II study using the combination of epirubicin and thalidomide in patients with unresectable and metastatic HCC... - Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liverShantanu K Gaur
Brigham and Women s Hospital, Angiography and Interventional Radiology, 75 Francis Street, Boston, MA 02115, USA
Cardiovasc Intervent Radiol 34:566-72. 2011.... - Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancerShuji Ogino
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 11:6650-6. 2005..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib... - Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinomaRihong Zhai
Department of Environmental Health, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
J Clin Oncol 28:2445-51. 2010..However, how multiple factors jointly affect EA risk remains unclear... - A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Dig Dis Sci 50:2218-23. 2005..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population... - Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumorsThomas E Clancy
Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Dig Dis Sci 51:877-84. 2006..Close monitoring of alkaline phosphatase levels may be useful when considering initiation or changes of therapy in patients with metastatic neuroendocrine tumors... - Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma riskRihong Zhai
Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
Carcinogenesis 29:2330-4. 2008..70; 95% CI, 1.04-2.73; P = 0.034). These results suggested that cigarette smoking modifies the association between VEGF polymorphisms and EA risk among Caucasians... - Phase II study of pemetrexed in patients with advanced neuroendocrine tumorsJennifer A Chan
Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
Cancer Chemother Pharmacol 66:961-8. 2010..Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors... - CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Virchows Arch 450:529-37. 2007..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy... - Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancerAndrew X Zhu
Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
Cancer Chemother Pharmacol 59:285-93. 2007.... - Pheochromocytoma and paraganglioma: imaging characteristicsJuan C Baez
Department of Radiology, Brigham and Women s Hospital, Boston, MA, USA
Cancer Imaging 12:153-62. 2012..Knowledge of the diverse appearance of pheochromocytomas and paragangliomas can result in early initial diagnosis or detection of disease recurrence thereby affecting patient management and prognosis... - Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testingJin Li
Department of Radiation Oncology, Divisions of Genomic Stability and DNA Repair, Physics and Radiation Therapy, Room JF514, 44 Binney Street, Boston, Massachusetts 02115, USA
Nat Med 14:579-84. 2008..COLD-PCR will transform the capabilities of PCR-based genetic testing, including applications in cancer, infectious diseases and prenatal identification of fetal alleles in maternal blood... - High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and lossMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Genes Chromosomes Cancer 47:591-603. 2008..This detailed study of an uncommon neoplasm provides a basis to investigate putative oncogenes and tumor suppressor genes in intestinal carcinoid tumors... - Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysisEva Maria Duerr
Gastrointestinal Unit, Department of Medicine, Cancer Center, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114, USA
Endocr Relat Cancer 15:243-56. 2008..This suggests that molecular profiling may enhance tumor classification schemes. Potential gene targets have also been identified, and PDGFR and RET are candidates that may represent novel therapeutic targets... - Carcinoid tumorsChandrajit P Raut
Harvard Medical School, Boston, Massachusetts, USA
Curr Probl Surg 43:383-450. 2006 - Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growthKotoyo Fujiki
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Gastroenterology 135:907-16, 916.e1-2. 2008..The molecular alterations that underlie carcinoid tumor pathogenesis remain poorly defined. The homeobox gene HOXC6 was highly up-regulated in human gastrointestinal carcinoid tumors, and we sought to define its pathogenic role... - A Large-scale genetic association study of esophageal adenocarcinoma riskChen Yu Liu
Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
Carcinogenesis 31:1259-63. 2010.... - Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomideAbraham B Schwarzberg
Harvard Medical School, Boston, Massachusetts, USA
Cancer Invest 25:249-55. 2007..Prophylaxis for Pneumocystis jiroveci pneumonia and varicella-zoster, as well as cytomegalovirus monitoring, should be considered in patients receiving temozolomide-based treatment... - Clinical presentation and management of carcinoid tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115 0684, USA
Hematol Oncol Clin North Am 21:433-55; vii-viii. 2007..Preliminary reports of activity associated with agents targeting the vascular endothelial growth factor pathway suggest that such strategies may play a role in the future treatment of patients who have this disease... - Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapyJeffrey A Meyerhardt
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 23:8453-60. 2005..Although several comprehensive dietary questionnaires have been validated and calibrated in healthy populations, similar studies have not been performed among cancer patients... - Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samplesJin Li
Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Clin Chem 52:624-33. 2006..CONCLUSION: The simplicity, versatility, reliability, and low cost of aQRT-PCR make it suitable for genetic analysis of clinical specimens... - Emerging therapies for the treatment of patients with advanced neuroendocrine tumorsJennifer A Chan
Dana Farber Cancer Institute, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA
Expert Opin Emerg Drugs 12:253-70. 2007..Ongoing randomized studies should help better define the role these agents will play in the future treatment of patients with this disease... - Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinomaRoss L Levine
Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
Clin Adv Hematol Oncol 1:99-100; discussion 100. 2003 - Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasmaJin Li
Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Brigham and Women's Hospital, Level L2, Radiation Therapy, 75 Francis St, Boston, MA 02115, USA
J Mol Diagn 8:22-30. 2006.... - F-18 FDG PET/CT in the diagnosis and management of a pericardiac paragangliomaNiall Sheehy
Department of Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Clin Nucl Med 33:545-6. 2008 - Neuroendocrine tumorsOrlo H Clark
Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA
J Natl Compr Canc Netw 4:102-38. 2006 - Combination chemotherapy for advanced pancreatic cancer--has its time finally come?Matthew H Kulke
Lancet Oncol 6:352-3. 2005 - Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumorsA David McCollum
Baylor University Medical Center Charles A Sammons Cancer Center, Dallas, Texas 75246, USA
Am J Clin Oncol 27:485-8. 2004..However, a recent review failed to confirm high antitumor activity in patients with advanced PETs... - The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancerA David McCollum
Texas Oncology, PA, and Baylor Sammons Cancer Center, Dallas, TX 75246, USA
Am J Clin Oncol 29:40-4. 2006..We conducted a multicenter, phase II study to examine the combination of capecitabine and thalidomide (Cape/Thal) in patients with refractory metastatic CRC... - Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomasEunice L Kwak
Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
Clin Cancer Res 12:4283-7. 2006..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers... - A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studiesPenelope A Bradbury
Princess Margaret Hospital Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario, Canada
Cancer Epidemiol Biomarkers Prev 17:204-11. 2008..Using clinical trial and epidemiologic methods, we assessed the quality of prognostic and outcomes data obtainable from a large case-control study of lung cancer...